UTHR - United Therapeutics Corporation

UTHR - United Therapeutics Corporation

https://www.unither.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

UTHR Stock Hits Record High on Tyvaso Meeting IPF Study Goals

Zacks Commentary • 1 week, 4 days ago • score: 0.47

United Therapeutics hit a record high after its Tyvaso study in idiopathic pulmonary fibrosis met key goals and showed broad patient benefits.

Why Is United Therapeutics Stock Rallying On Tuesday? - United Therapeutics ( NASDAQ:UTHR )

Benzinga • 1 week, 6 days ago • score: 0.24

Tyvaso improved absolute FVC by 95.6 mL over placebo at week 52 in IPF patients. United Therapeutics plans FDA talks in 2025; TETON-1 data expected by mid-2026. Get Discounted Real-Time Trade Alerts For a Volatile Market ( Labor Day Special )

Why Is United Therapeutics ( UTHR ) Up 11.9% Since Last Earnings Report?

Zacks Commentary • 2 weeks, 3 days ago • score: 0.28

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy - MannKind ( NASDAQ:MNKD ) , United Therapeutics ( NASDAQ:UTHR )

Benzinga • 2 weeks, 5 days ago • score: 0.48

DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation MNKD today announced that United Therapeutics Corporation UTHR has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder inhalation therapy.

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

GlobeNewswire • 2 weeks, 5 days ago • score: 0.37

DANBURY, Conn. and BOSTON, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- MannKind Corporation ( Nasdaq: MNKD ) today announced that United Therapeutics Corporation ( Nasdaq: UTHR ) has exercised its option-granted under the companies' 2018 license and collaboration agreement-to develop a second dry powder ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

52W High

$436.95

52W Low

$266.98

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.62

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

15.63

Forward P/E (<15 better)

13.83

EV/EBITDA (<8 favorable)

8.68

EV/Revenue (<3 favorable)

4.87

P/S (TTM) (<3 favorable)

5.89

P/B (<3 favorable)

2.53

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.77%

Institutions (25–75% balanced)

99.51%

Shares Outstanding

45,226,300

Float

41,986,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

3,077,800,000

Gross Profit (TTM)

2,738,700,000

EPS (TTM)

25.63

Profit Margin (>10% good)

0.40%

Operating Margin (TTM) (higher better)

0.46%

ROE (TTM) (>15% strong)

0.19%

EPS YoY (Quarterly) (>10% good)

0.10

Revenue YoY (Quarterly) (>8% good)

0.12

Momentum

Bearish momentum

Value

33.0499

Previous

32.7979

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025